Decreasing mortality from non-Hodgkin lymphoma in Australia

Internal Medicine Journal

Volumn 38, Issue 12, 2008, Pages 921-924

  Coory, M ^a   Gill, D ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Epidemiology; Mortality; Non Hodgkin lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

ARTICLE; AUSTRALIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER RELAPSE; CANCER SURVIVAL; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MORBIDITY; MORTALITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

AGE FACTORS; AGED; AUSTRALIA; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MORTALITY; QUEENSLAND; REGISTRIES;

EID: 58149201303     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01809.x     Document Type: Article

References (16)

1. Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkin's lymphoma. Acta Oncologica 2006 45 : 258 71.
2. Alexander D, Mink P, Adami H, Chang E, Cole P, Mandel J et al. The non-Hodgkin lymphomas: a review of the epidemiological literature. Int J Cancer 2007 120 : 1 39.
3. Liu S, Semenciw R, Mao Y. Increasing incidence of non-Hodgkin lymphoma in Canada, 1970-1996: age-period-cohort analysis. Hematol Oncol 2003 21 : 57 66.
4. Adamson P, Bray F, Costantini A, Tao M, Weiderpass E, Roman E. Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer 2007 43 : 391 401.
5. Jaffe E, Stein H, Vardiman J. Pathology and genetics of tumours of the hematopoietic and lymphoid tissues. In : Jaffe E, Stein H, Vardiman J, eds. World Health Organisation Classification of Tumours. Lyon : IARC Press 2001.
6. National Cancer Institute. Cancer Stat Fact Sheets, Non-Hodgkin Lymphoma. 2006 cited 2008 Sep]; Available from URL : http://seer.cancer.gov/statfacts
7. Kim H, Fay M, Feuer E, Midthume D. Permutation tests for joinpoint regression with application to cancer rates. Stat Med 2000 19 : 335 51.
8. Espey D, Wu X, Swan J, Wiggins C, Jim M, Ward E et al. Annual report to the Nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007 110 : 2119 52.
9. Rothman K. Epidemiology: An Introduction. New York : Oxford University Press 2002.
10. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993 329 : 987 94.
11. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004 104 : 1258 65.
12. Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA. Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev 2004 13 : 138 43.
13. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005 23 : 5027 33.
14. Forstpointner R, Dreyling M, Repp R et al. The addition of rituximab to a combination of fludarabine, cyclophosamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantel cell lymphomas: results of a prospective randomised study of the German Low-Grade Lymphoma Study Group. Blood 2004 104 : 3064 71.
15. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-cell B lymphoma. N Engl J Med 2002 346 : 235 42.
16. Pfreundschuth M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphomas: a randomised trial by the Mab Thera International Trial (MinT) group. Lancet Oncol 2006 7 : 379 91.